Palatin Technologies (PTN) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palatin Technologies (PTN) has outperformed TScan Therapeutics (TCRX) over the past year, gaining 19.4% versus a loss of 89.0%. Over five years, TCRX leads with a -96.5% price change compared with -98.4% for PTN. TScan Therapeutics is the larger company by market cap ($16.1 million vs $15.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTN | TCRX |
|---|---|---|
| Share price | $8.60 | $0.238 |
| Market cap | $15.32M | $16.13M |
| 1-day change | -4.55% | +4.29% |
| YTD return | -44.08% | -76.20% |
| 1-year return | +19.44% | -89.03% |
| 5-year return | -98.40% | -96.47% |
| EPS (TTM) | $-2.96 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.00 | $2.57 |
| 52-week low | $5.61 | $0.224 |
| Distance from 52-week high | -72.26% | -90.74% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +522.09% | +320.17% |
| Average volume | 63.25K | 784.00K |
| Shares outstanding | 1.78M | 63.50M |
| Employees | 25 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed TCRX by 108.5 percentage points over the past year.
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
PTN vs TCRX FAQ
Which is bigger, Palatin Technologies or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $16.13M compared with $15.32M for Palatin Technologies (PTN).
Which stock has performed better over the past year, PTN or TCRX?
PTN returned +19.44% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Palatin Technologies and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Palatin Technologies and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.